| Literature DB >> 26580595 |
Simone Nicolardi1, Bogdan Bogdanov2, André M Deelder3, Magnus Palmblad4, Yuri E M van der Burgt5.
Abstract
Fourier transform mass spectrometry (FTMS) is the method of choice for measurements that require ultra-high resolution. The establishment of Fourier transform ion cyclotron resonance (FTICR) MS, the availability of biomolecular ionization techniques and the introduction of the Orbitrap™ mass spectrometer have widened the number of FTMS-applications enormously. One recent example involves clinical proteomics using FTICR-MS to discover and validate protein biomarker signatures in body fluids such as serum or plasma. These biological samples are highly complex in terms of the type and number of components, their concentration range, and the structural identity of each species, and thus require extensive sample cleanup and chromatographic separation procedures. Clearly, such an elaborate and multi-step sample preparation process hampers high-throughput analysis of large clinical cohorts. A final MS read-out at ultra-high resolution enables the analysis of a more complex sample and can thus simplify upfront fractionations. To this end, FTICR-MS offers superior ultra-high resolving power with accurate and precise mass-to-charge ratio (m/z) measurement of a high number of peptides and small proteins (up to 20 kDa) at isotopic resolution over a wide mass range, and furthermore includes a wide variety of fragmentation strategies to characterize protein sequence and structure, including post-translational modifications (PTMs). In our laboratory, we have successfully applied FTICR "next-generation" peptide profiles with the purpose of cancer disease classifications. Here we will review a number of developments and innovations in FTICR-MS that have resulted in robust and routine procedures aiming for ultra-high resolution signatures of clinical samples, exemplified with state-of-the-art examples for serum and saliva.Entities:
Keywords: FTICR-MS; clinical cohort; instrumental development; mass spectrometry; profiling; proteomics; saliva; serum; solid-phase extraction; ultra-high resolving power
Mesh:
Substances:
Year: 2015 PMID: 26580595 PMCID: PMC4661870 DOI: 10.3390/ijms161126012
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Early (in blue) and current (in green) matrix-assisted laser desorption/ionization (MALDI)-based serum peptide and protein profiles obtained after reversed-phase (RP) C18-magnetic bead cleanup. The MALDI-time-of-flight (TOF) profile in the upper panel is composed of a low-resolution linear mode spectrum (up to m/z-value 11,000) and a high-resolution reflectron mode spectrum (up to m/z-value 4600); in the lower panel a MALDI- Fourier transform ion cyclotron resonance (FTICR) profile of the same sample is shown.
Figure 2MALDI-FTICR (in orange) and electrospray ionization (ESI)-FTICR (in blue) saliva peptide and protein profiles obtained after RPC18-based cleanup. Multiply charged species in the ESI-FTICR profile (indicated with A and B) were selected for tandem mass spectrometry (MS/MS) analysis, with identification results shown at the bottom (in green).